Concepedia

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

Juan Macı́as, Karin Neukam, Josep Mallolas, Luís F. López‐Cortés, J. A. Cartón, Peré Domingo, Santiago Moreno, José Antonio Iribarren, Bonaventura Clotet, M Crespo,

HIV Clinical Trials · 2012 · 23 citations · 9 references

DOIFull text

Open access

Abstract

Regimens including EFV, NVP, or PI/r are generally safe in treatment-naïve HIV/HCV-coinfected patients. Grade 3-4 TE are less commonly seen with EFV than with PI/r. Discontinuations due to hepatotoxicity were less frequent for patients receiving EFV than for those treated with NVP.

References

9

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

Frank van Leth, Praphan Phanuphak, Kiat Ruxrungtham et al. · The Lancet · 2004 · 683 citations

, , +9

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections

Mark Sulkowski, David L. Thomas, Shruti H. Mehta et al. · Hepatology · 2002 · 521 citations

, , +21

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

Estebán Martínez, José Luís Blanco, Juan A. Arnaiz et al. · AIDS · 2001 · 351 citations

Fast Fibrosis Progression Between Repeated Liver Biopsies in Patients Coinfected with Human Immunodeficiency Virus/Hepatitis C Virus†

Juan Macı́as, Juan Berenguer, Miguel Á. Japón et al. · Hepatology · 2009 · 257 citations

Clinical progression of hepatitis C virus–related chronic liver disease in human immunodeficiency virus–infected patients undergoing highly active antiretroviral therapy

Juan A. Pineda, José Ángel García-García, Manuela Aguilar‐Guisado et al. · Hepatology · 2007 · 197 citations · Full text